Similar articles for PMID: 21114605

Year	Number of Results
2005	1
2007	3
2009	4
2010	5
2011	12
2012	18
2013	26
2014	22
2015	23
2016	14
2017	15
2018	9
2019	8
2020	9
2021	14
2022	7
2023	3
2024	0

1

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ. Taskinen MR, et al. Diabetes Obes Metab. 2011 Jan;13(1):65-74. doi: 10.1111/j.1463-1326.2010.01326.x. Diabetes Obes Metab. 2011. PMID: 21114605 Clinical Trial.

2

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Gomis R, et al. Diabetes Obes Metab. 2011 Jul;13(7):653-61. doi: 10.1111/j.1463-1326.2011.01391.x. Diabetes Obes Metab. 2011. PMID: 21410628 Clinical Trial.

3

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

Owens DR, Swallow R, Dugi KA, Woerle HJ. Owens DR, et al. Diabet Med. 2011 Nov;28(11):1352-61. doi: 10.1111/j.1464-5491.2011.03387.x. Diabet Med. 2011. PMID: 21781152 Clinical Trial.

4

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, Woerle HJ, Dugi KA. Forst T, et al. Diabet Med. 2010 Dec;27(12):1409-19. doi: 10.1111/j.1464-5491.2010.03131.x. Diabet Med. 2010. PMID: 21059094 Clinical Trial.

5

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Haak T, et al. Diabetes Obes Metab. 2012 Jun;14(6):565-74. doi: 10.1111/j.1463-1326.2012.01590.x. Epub 2012 Mar 21. Diabetes Obes Metab. 2012. PMID: 22356132 Clinical Trial.

6

Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.

Bajaj M, Gilman R, Patel S, Kempthorne-Rawson J, Lewis-D'Agostino D, Woerle HJ. Bajaj M, et al. Diabet Med. 2014 Dec;31(12):1505-14. doi: 10.1111/dme.12495. Epub 2014 Jul 7. Diabet Med. 2014. PMID: 24824197 Free PMC article. Clinical Trial.

7

Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.

Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M. Ross SA, et al. Diabetes Obes Metab. 2015 Feb;17(2):136-44. doi: 10.1111/dom.12399. Epub 2014 Nov 19. Diabetes Obes Metab. 2015. PMID: 25298165 Clinical Trial.

8

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.

Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ. Barnett AH, et al. Diabetes Obes Metab. 2012 Dec;14(12):1145-54. doi: 10.1111/dom.12011. Epub 2012 Oct 1. Diabetes Obes Metab. 2012. PMID: 22974280 Clinical Trial.

9

Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.

Yki-Järvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, Woerle HJ. Yki-Järvinen H, et al. Diabetes Care. 2013 Dec;36(12):3875-81. doi: 10.2337/dc12-2718. Epub 2013 Sep 23. Diabetes Care. 2013. PMID: 24062327 Free PMC article. Clinical Trial.

10

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ. Lewin AJ, et al. Clin Ther. 2012 Sep;34(9):1909-19.e15. doi: 10.1016/j.clinthera.2012.07.008. Epub 2012 Aug 29. Clin Ther. 2012. PMID: 22939034 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

161 results

Results by year